Wednesday, 18 June 2014

Mesenchymal stem cell-based treatment for microvascular and secondary complications of Diabetes mellitus

MSC administration has significant potential in the treatment of diabetic microvascular and secondary complications but challenges remain in terms of engraftment, persistence, tissue targeting, and cell manufacture (Frontiers in Endocrinology)


Differential reduction in corneal nerve fiber length in patients with type 1 or type 2 diabetes mellitus

Corneal confocal microscopy of the sub-basal nerve plexus may be an indicator of early peripheral nerve degeneration in type 1 DM. Type of diabetes, in addition to degree of neuropathy, may influence the extent of corneal nerve damage (Diabetes and Its Complications)


Resubmission of New Drug Application for empagliflozin to FDA

Type 2 diabetes: Boehringer Ingelheim and Eli Lilly and Company announce resubmission of New Drug Application for empagliflozin to FDA (Lilly)

No comments:

Post a Comment